2026 Geromedicine Conference | Dr Weilan Wang, Yong Loo Lin School of Medicine, NUS
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →About this video
Creator description · original textText language: English
Watch the oral poster presentation by Dr Weilan Wang, Senior Research Fellow at the NUS Academy for Healthy Longevity, Yong Loo Lin School of Medicine, NUS, at the NUS AHL’s 2026 Geromedicine Conference.
This presentation focuses on ABLE, a study investigating the safety and efficacy of alpha-ketoglutarate supplementation in middle-aged, healthy adults. Dr Wang discusses the study’s examination of alpha-ketoglutarate in relation to biological DNA methylation age and selected mechanisms of ageing.
By exploring whether supplementation may influence biological measures associated with ageing, the study contributes to ongoing research into interventions that could support healthier ageing and healthspan. The presentation also highlights the importance of evaluating potential longevity interventions through carefully designed clinical research, including assessment of both safety and efficacy.
The 2026 Geromedicine Conference brings together researchers, clinicians, and industry experts to advance the science of ageing and explore evidence-informed approaches to geromedicine, healthy longevity, and healthspan optimisation.
#Geromedicine #HealthyLongevity #AlphaKetoglutarate #DNAMethylation #BiologicalAge #MechanismsOfAgeing #HealthyAgeing #Healthspan #AgeingResearch #Geroscience #ClinicalResearch #NUSMedicine #NUSAcademyForHealthyLongevity
NUS Academy for Healthy Longevity · 8 min · Source published: 2026-09-01
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.